Welcome to our dedicated page for Vicarious Surgical SEC filings (Ticker: RBOT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vicarious Surgical Inc. filings document the company's robotic surgery business, capital structure, governance actions, and public-market status. Recent 8-K reports cover operating results, financial condition, executive employment agreement amendments, and NYSE delisting proceedings for the company's Class A common stock, which is quoted on the OTC market under RBOT.
Proxy and shareholder-vote filings describe amendments to the certificate of incorporation related to a reverse stock split authorization and the voting mechanics of the company's Class A and Class B common stock. Form 25 and related reports document removal of the Class A common stock from NYSE listing and registration under Section 12(b).
Vicarious Surgical Inc. (RBOT) Form 144 shows a proposed sale of 239 shares of Class A common stock through UBS Financial Services with an aggregate market value of $1,386 and an approximate sale date of 09/03/2025 on the NYSE. The filing reports the securities were acquired on 09/02/2025 via a restricted stock lapse from Vicarious Surgical Inc. and indicates 696 shares were acquired in that transaction.
The filing also discloses three prior sales by the listed seller, Sammy Khalifa, during the past three months: 239 shares on 06/03/2025 for $1,641, 223 shares on 06/23/2025 for $1,650, and 653 shares on 08/20/2025 for $3,801. The notice includes the standard signature representation that the seller is not aware of undisclosed material adverse information about the issuer.
Donald F. Tang, a director of Vicarious Surgical Inc. (RBOT), reported an open-market sale of 2,753 shares of Class A common stock on 08/26/2025 at a weighted average price of $6.6965 per share. Following the sale, the filing shows Mr. Tang beneficially owned 40,425 shares. The Form 4 was executed by an attorney-in-fact on 08/27/2025. The filing discloses the weighted average price represents multiple trades that ranged from $6.64 to $7.15 per share, and the reporting person offers to provide trade-specific quantities and prices to SEC staff or the company on request.
Khalifa Sammy, listed as Chief Technology Officer, director and a 10% owner of Vicarious Surgical Inc. (RBOT), reported a non-discretionary sale on 08/20/2025 of 653 shares of Class A common stock to satisfy tax withholding obligations arising from restricted stock units granted on May 19, 2022. The weighted average sale price was $6.0422, with individual trades ranging from $5.90 to $6.32. After the transaction, the reporting person beneficially owned 34,754 shares directly. The Form 4 was filed by one reporting person and signed on 08/21/2025 by an attorney-in-fact.
Adam David Sachs, President and Director of Vicarious Surgical Inc. (RBOT), sold 817 shares of Class A common stock on 08/20/2025 to satisfy tax withholding on vested restricted stock units. The sales were executed as a mandatory "sell to cover" under the company's equity plan and are not discretionary trades. The weighted average sale price was $6.0312 per share, with individual trade prices ranging from $5.90 to $6.32. After the transaction Sachs beneficially owned 49,627 shares. The Form 4 was signed by an attorney-in-fact on 08/21/2025.
Director Donald F. Tang reported open-market dispositions of Vicarious Surgical Inc. (RBOT) common stock. He sold 100 shares on 08/19/2025 at $6.68 and 2,059 shares on 08/20/2025 at $6.04, reducing his direct holdings from 45,237 shares to 43,178 shares. The form is signed by an attorney-in-fact and does not disclose any derivative transactions or additional context.
Form 144 notice for Vicarious Surgical Inc. (RBOT) reports a proposed sale of Class A common stock through UBS Financial Services. The filing shows 817 shares proposed for sale with an aggregate market value of $5,212.46 and lists the approximate sale date as 08/20/2025 on the NYSE. The securities were acquired by the reporting person on 08/19/2025 as a restricted stock lapse, with 2,378 shares noted as acquired on that date. The filing also discloses three sales by the same seller in the past three months: 817 shares on 05/20/2025 for $5,961, 463 shares on 06/03/2025 for $3,210, and 279 shares on 06/23/2025 for $2,067. The notice includes the seller’s signed representation that they are not aware of any undisclosed material adverse information about the issuer.
Vicarious Surgical Inc. (RBOT) filing is a Form 144 notice reporting proposed sales of Class A common stock by an insider. The filing lists a planned sale of 653 shares through UBS Financial Services with an aggregate market value of $4,166.14 and an approximate sale date of 08/20/2025 on the NYSE. The securities were acquired on 08/19/2025 by restricted stock lapse, showing 1,902 shares acquired in that transaction. The filer also disclosed three prior sales in the past three months totaling 1,115 shares with gross proceeds of $8,039 on 05/20/2025, 06/03/2025, and 06/23/2025. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Vicarious Surgical Inc. remains pre-revenue and reported a six-month net loss of $28.6 million and a three-month net loss of $13.2 million. Total assets declined to $40.9 million from $67.7 million, driven by lower cash and short-term investments. Cash and cash equivalents were $3.9 million and short-term investments were $20.1 million, totaling $23.96 million at June 30, 2025.
Management disclosed that these funds are insufficient to support operations for the next 12 months, raising substantial doubt about the company's ability to continue as a going concern and requiring pursuit of additional equity or debt financing. The company reduced operating expenses year-over-year (R&D, G&A and S&M), improving loss from operations by ~13% for the six-month comparison. The NYSE notified the company of non-compliance with market capitalization standards but accepted the company’s cure plan for the specified review period. A CEO appointment was announced as a subsequent event.
Vicarious Surgical Inc. furnished a Current Report announcing that it issued a press release with its results for the second quarter ended June 30, 2025 and providing a business update. The 8-K attaches that press release as Exhibit 99.1 and includes an Inline XBRL cover page file as Exhibit 104. The filing states the furnished materials are not "filed" for purposes of the Exchange Act and are not incorporated by reference elsewhere unless explicitly stated. The report does not include financial tables, numerical earnings or balance sheet figures within the filing itself; readers must consult the attached press release for detailed results.
Vicarious Surgical director Ahmad Fuad acquired a stock option on June 27, 2025 giving the right to purchase 8,003 Class A common shares at an exercise price of $7.61. The option is reported as directly beneficially owned and has an expiration date of June 26, 2035.
The filing states the shares underlying the option will vest on June 27, 2026 (or one day prior to the issuer's next annual meeting), subject to continued service. The Form 4 was executed by an attorney-in-fact on August 11, 2025. The disclosure shows a routine director option grant with defined exercise price, vesting schedule, and expiration; no sales or dispositions are reported here.